Dong Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dong Yang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Shujun Sun
Department of Anesthesiology, Union hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publications - Xiangdong Chen
Department of Anesthesiology, Union hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publications QingHua Yin
Department of Pain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publicationsShuJun Sun
Department of Pain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publicationsShujun Sun
Department of Pain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Wuhan, 430022, China
2 shared publicationsTianHao Zou
Department of Pain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications
Latest Publications
- Open Access
- 13 June 2026
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (4) , 1023-1048
Neuromodulation Techniques Alleviating Neuropathic Pain by Targeting Microglia: A Narrative Review
Neuropathic pain (NP) has attracted growing attention in recent years; however, its pathogenesis remains incompletely understood, and therapeutic options remain limited. Neuromodulation techniques have demonstrated considerable promise in managing NP, offering advantages including noninvasiveness, minimal discomfort, and precise anatomical targeting. Nevertheless, therapeutic parameters have yet to be standardized as a result of variability across multiple factors such as modality type, stimulation site, and treatment duration. Microglia, as the resident immune cells of the central nervous system, play a pivotal role in the development and maintenance of NP. Following nerve injury, microglia become activated and release various inflammatory mediators and signaling molecules that modulate pain transmission pathways. Importantly, emerging evidence indicates that neuromodulation can regulate microglial activation states and associated inflammatory cascades through either indirect or direct pathways. Indirect mechanisms involve modulating neuronal activity and downstream signaling, thereby influencing microglial functional phenotypes. Direct mechanisms act via microglia-specific properties such as electrophysiological sensitivity, receptor expression, or local field potential interactions. This review synthesizes current evidence on the mechanisms and recent advances in microglia-targeted neuromodulation strategies for NP relief, distinguishing between preclinical and clinically validated findings, and aiming to provide a theoretical foundation for future research.
- 13 June 2026
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (4) , 1023-1048
Open AccessNeuromodulation Techniques Alleviating Neuropathic Pain by Targeting Microglia: A Narrative Review
Neuropathic pain (NP) has attracted growing attention in recent years; however, its pathogenesis remains incompletely understood, and therapeutic options remain limited. Neuromodulation techniques have demonstrated considerable promise in managing NP, offering advantages including noninvasiveness, minimal discomfort, and precise anatomical targeting. Nevertheless, therapeutic parameters have yet to be standardized as a result of variability across multiple factors such as modality type, stimulation site, and treatment duration. Microglia, as the resident immune cells of the central nervous system, play a pivotal role in the development and maintenance of NP. Following nerve injury, microglia become activated and release various inflammatory mediators and signaling molecules that modulate pain transmission pathways. Importantly, emerging evidence indicates that neuromodulation can regulate microglial activation states and associated inflammatory cascades through either indirect or direct pathways. Indirect mechanisms involve modulating neuronal activity and downstream signaling, thereby influencing microglial functional phenotypes. Direct mechanisms act via microglia-specific properties such as electrophysiological sensitivity, receptor expression, or local field potential interactions. This review synthesizes current evidence on the mechanisms and recent advances in microglia-targeted neuromodulation strategies for NP relief, distinguishing between preclinical and clinically validated findings, and aiming to provide a theoretical foundation for future research.
- Open Access
- 1 October 2025
- Published by The Korean Society of Anesthesiologists in Korean Journal of Anesthesiology
- Vol. 78 (5) , 471-481
The 90% minimum effective volume and concentration of lidocaine for ultrasound-guided stellate ganglion blocks in adults: a biased-coin design, up-and-down sequential allocation trial
Background: As ultrasound imaging technology matured, stellate ganglion blocks (SGBs) have become increasingly precise and safe, and their use in clinical practice has become widespread. However, the 90% minimum effective volume (MEV90) and concentration (MEC90) of lidocaine for ultrasound-guided SGB remain unclear. We aimed to determine the MEV90 and MEC90 of lidocaine used in ultrasound-guided SGBs.Methods: Patients with indications for an SGB were recruited, without restrictions on sex or disease type. In this two-part study, we first determined the MEV90, and then used these results to determine the MEC90. The MEV90 and MEC90 of lidocaine for each subsequent patient were determined based on the previous patient’s response, using a biased-coin design, up-and-down sequential allocation trial. The lidocaine volume and concentration intervals were 0.2 ml and 0.1%, respectively.Results: In total, 110 patients were enrolled (58 and 52 patients in the MEV90 and MEC90 studies, respectively). The MEV90 for 1% lidocaine was found to be 3.83 ml (95% CI [3.19–3.91]) and the extrapolated MEV99 was 3.97 ml (95% CI [3.95–5.29]). The MEC90 for lidocaine (4.0 ml) was found to be 0.38% (95% CI [0.32–0.41]) and the extrapolated MEC99 was 0.47% (95% CI [0.46–2.55]). Four patients in this study developed hoarseness, but no serious adverse events occurred.Conclusions: For ultrasound-guided SGB in adults, we have determined the MEV90 of 1% lidocaine as 3.83 ml, and identified the MEC90 of 4 ml of lidocaine as 0.38%.
- 1 October 2025
- Published by The Korean Society of Anesthesiologists in Korean Journal of Anesthesiology
- Vol. 78 (5) , 471-481
Open AccessThe 90% minimum effective volume and concentration of lidocaine for ultrasound-guided stellate ganglion blocks in adults: a biased-coin design, up-and-down sequential allocation trial
Background: As ultrasound imaging technology matured, stellate ganglion blocks (SGBs) have become increasingly precise and safe, and their use in clinical practice has become widespread. However, the 90% minimum effective volume (MEV90) and concentration (MEC90) of lidocaine for ultrasound-guided SGB remain unclear. We aimed to determine the MEV90 and MEC90 of lidocaine used in ultrasound-guided SGBs.Methods: Patients with indications for an SGB were recruited, without restrictions on sex or disease type. In this two-part study, we first determined the MEV90, and then used these results to determine the MEC90. The MEV90 and MEC90 of lidocaine for each subsequent patient were determined based on the previous patient’s response, using a biased-coin design, up-and-down sequential allocation trial. The lidocaine volume and concentration intervals were 0.2 ml and 0.1%, respectively.Results: In total, 110 patients were enrolled (58 and 52 patients in the MEV90 and MEC90 studies, respectively). The MEV90 for 1% lidocaine was found to be 3.83 ml (95% CI [3.19–3.91]) and the extrapolated MEV99 was 3.97 ml (95% CI [3.95–5.29]). The MEC90 for lidocaine (4.0 ml) was found to be 0.38% (95% CI [0.32–0.41]) and the extrapolated MEC99 was 0.47% (95% CI [0.46–2.55]). Four patients in this study developed hoarseness, but no serious adverse events occurred.Conclusions: For ultrasound-guided SGB in adults, we have determined the MEV90 of 1% lidocaine as 3.83 ml, and identified the MEC90 of 4 ml of lidocaine as 0.38%.
- Open Access
- 16 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (9) , 6318-6329
CXCL13/CXCR5: a new target for pain treatment
Pain is a significant global health burden, and current treatments often fail to provide adequate relief due to an incomplete understanding of its mechanisms. This review integrates emerging evidence highlighting the CXCL13/CXCR5 chemokine pathway as a crucial mediator across various pain states, including nociceptive, inflammatory, and neuropathic pain. CXCL13 and CXCR5 are substantially upregulated in pain-related regions such as the spinal cord, dorsal root ganglia (DRG), and cerebrospinal fluid following nerve injury, inflammation, and in conditions like bone cancer or diabetes. The key mechanisms through which they contribute to pain include enhancing neuronal excitability by increasing Nav1.8 sodium channel currents in DRG neurons via p38 MAPK signaling, promoting neuroinflammation by activating NF-κB, ERK, and JNK pathways, which drive the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β) and immune cell infiltration, and activating glial cells, where CXCL13/CXCR5 signaling promotes astrocyte reactivity and indirectly activates microglia, thereby amplifying central sensitization. Genetic knockdown or pharmacological inhibition of CXCL13/CXCR5 has been shown to significantly reduce pain hypersensitivity in preclinical models. The pathway’s high tissue specificity in pain pathways and its multifaceted regulation of pain mechanisms make it a promising novel therapeutic target. Future research should address CXCL13/CXCR5 interactions with other pain-related pathways (e.g., CXCL12/CXCR4), explore non-GPCR signaling (e.g., β-arrestins), and validate its potential as a clinical biomarker to guide targeted analgesic development.
- 16 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (9) , 6318-6329
Open AccessCXCL13/CXCR5: a new target for pain treatment
Pain is a significant global health burden, and current treatments often fail to provide adequate relief due to an incomplete understanding of its mechanisms. This review integrates emerging evidence highlighting the CXCL13/CXCR5 chemokine pathway as a crucial mediator across various pain states, including nociceptive, inflammatory, and neuropathic pain. CXCL13 and CXCR5 are substantially upregulated in pain-related regions such as the spinal cord, dorsal root ganglia (DRG), and cerebrospinal fluid following nerve injury, inflammation, and in conditions like bone cancer or diabetes. The key mechanisms through which they contribute to pain include enhancing neuronal excitability by increasing Nav1.8 sodium channel currents in DRG neurons via p38 MAPK signaling, promoting neuroinflammation by activating NF-κB, ERK, and JNK pathways, which drive the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β) and immune cell infiltration, and activating glial cells, where CXCL13/CXCR5 signaling promotes astrocyte reactivity and indirectly activates microglia, thereby amplifying central sensitization. Genetic knockdown or pharmacological inhibition of CXCL13/CXCR5 has been shown to significantly reduce pain hypersensitivity in preclinical models. The pathway’s high tissue specificity in pain pathways and its multifaceted regulation of pain mechanisms make it a promising novel therapeutic target. Future research should address CXCL13/CXCR5 interactions with other pain-related pathways (e.g., CXCL12/CXCR4), explore non-GPCR signaling (e.g., β-arrestins), and validate its potential as a clinical biomarker to guide targeted analgesic development.
- 20 November 2024
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (1) , 1-13
Maresin-1 Ameliorates Sepsis-Induced Microglial Activation Through Modulation of the P38 MAPK Pathway
Sepsis is a life-threatening disease characterized by a dysregulated immune response to infection, often leading to neuroinflammation. As a known immunomodulator, Maresin-1 (MaR1) may have potential applications in the treatment of sepsis-induced neuroinflammation, but its effects in this context are unknown. We used a mouse cecum ligation and puncture (CLP)-induced sepsis model and an in vitro lipopolysaccharide (LPS)-induced neuroinflammatory model of BV2 microglia. Expression of microglial cell markers (IBA1, CD11B, CD68, CD86 and CD206) and pro-inflammatory markers (iNOS and COX2) was assessed. The role of MaR1 in regulating the P38 MAPK pathway was explored using the P38 MAPK inhibitor SB203580. In the CLP model, an increased proportion of M1-type microglia was observed, and MaR1 was able to reverse it. However, the combination of SB203580 and MaR1 did not enhance the therapeutic effect compared to SB20580 alone. In vitro experiments, MaR1 inhibited LPS-induced P38 MAPK nuclear translocation and decreased the expression of pro-inflammatory markers such as iNOS and COX2. As with the animal results, no stacking effect could be obtained with the co-administration of SB203580 and MaR1. Our findings suggest that MaR1 attenuates sepsis-induced neuroinflammation mainly by inhibiting phosphorylation of P38 MAPK in microglial cells. This suggests that MaR1 may have a potential therapeutic role in the treatment of sepsis neuroinflammation. Graphical Abstract Under sepsis, the phosphorylation of P38 MAPK in the brain is increased, which may cause resting microglia in the brain in the transformation to M1-type microglia. At the same time, P38 MAPK in microglia translocates to the nucleus and increases its phosphorylation level, which may promote microglia to trigger neuroinflammation and further induce neuronal degeneration. MaR1 can inhibit the above process. This figure was created by Figdraw
- 20 November 2024
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (1) , 1-13
Maresin-1 Ameliorates Sepsis-Induced Microglial Activation Through Modulation of the P38 MAPK Pathway
Sepsis is a life-threatening disease characterized by a dysregulated immune response to infection, often leading to neuroinflammation. As a known immunomodulator, Maresin-1 (MaR1) may have potential applications in the treatment of sepsis-induced neuroinflammation, but its effects in this context are unknown. We used a mouse cecum ligation and puncture (CLP)-induced sepsis model and an in vitro lipopolysaccharide (LPS)-induced neuroinflammatory model of BV2 microglia. Expression of microglial cell markers (IBA1, CD11B, CD68, CD86 and CD206) and pro-inflammatory markers (iNOS and COX2) was assessed. The role of MaR1 in regulating the P38 MAPK pathway was explored using the P38 MAPK inhibitor SB203580. In the CLP model, an increased proportion of M1-type microglia was observed, and MaR1 was able to reverse it. However, the combination of SB203580 and MaR1 did not enhance the therapeutic effect compared to SB20580 alone. In vitro experiments, MaR1 inhibited LPS-induced P38 MAPK nuclear translocation and decreased the expression of pro-inflammatory markers such as iNOS and COX2. As with the animal results, no stacking effect could be obtained with the co-administration of SB203580 and MaR1. Our findings suggest that MaR1 attenuates sepsis-induced neuroinflammation mainly by inhibiting phosphorylation of P38 MAPK in microglial cells. This suggests that MaR1 may have a potential therapeutic role in the treatment of sepsis neuroinflammation. Graphical Abstract Under sepsis, the phosphorylation of P38 MAPK in the brain is increased, which may cause resting microglia in the brain in the transformation to M1-type microglia. At the same time, P38 MAPK in microglia translocates to the nucleus and increases its phosphorylation level, which may promote microglia to trigger neuroinflammation and further induce neuronal degeneration. MaR1 can inhibit the above process. This figure was created by Figdraw
- Open Access
- 28 September 2024
- Published by Springer Nature in Pain and Therapy
- Vol. 13 (6) , 1387-1406
Peripheral Nerve Stimulation for Neuropathic Pain Management: A Narrative Review
This narrative review examines the therapeutic efficacy of peripheral nerve stimulation (PNS) in the treatment of neuropathic pain (NP), a type of pain arising from lesions or diseases of the somatosensory system with a global prevalence ranging from 6.90% to 10.00%. Traditional pharmacological interventions often fall short for many persons, highlighting the need for alternative treatments such as PNS, which has demonstrated significant promise with minimal side effects. The review summarizes the effectiveness of PNS in various NP conditions, including trigeminal neuralgia and postherpetic neuralgia, and underscores the need for further research to refine treatment approaches. The mechanism of PNS is discussed, involving the activation of non-nociceptive Aβ fibers and modulation of neurotransmitters, and offering pain relief through both peripheral and central pathways. Despite the proven efficacy of PNS, challenges remain, including the need for randomized controlled trials and the optimization of stimulation parameters. The review concludes that PNS is a promising treatment modality for NP, warranting additional high-quality trials to solidify its role in clinical practice.
- 28 September 2024
- Published by Springer Nature in Pain and Therapy
- Vol. 13 (6) , 1387-1406
Open AccessPeripheral Nerve Stimulation for Neuropathic Pain Management: A Narrative Review
This narrative review examines the therapeutic efficacy of peripheral nerve stimulation (PNS) in the treatment of neuropathic pain (NP), a type of pain arising from lesions or diseases of the somatosensory system with a global prevalence ranging from 6.90% to 10.00%. Traditional pharmacological interventions often fall short for many persons, highlighting the need for alternative treatments such as PNS, which has demonstrated significant promise with minimal side effects. The review summarizes the effectiveness of PNS in various NP conditions, including trigeminal neuralgia and postherpetic neuralgia, and underscores the need for further research to refine treatment approaches. The mechanism of PNS is discussed, involving the activation of non-nociceptive Aβ fibers and modulation of neurotransmitters, and offering pain relief through both peripheral and central pathways. Despite the proven efficacy of PNS, challenges remain, including the need for randomized controlled trials and the optimization of stimulation parameters. The review concludes that PNS is a promising treatment modality for NP, warranting additional high-quality trials to solidify its role in clinical practice.
- Open Access
- 29 February 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1353882
Digital subtraction angiography-guided peripheral nerve stimulation via the foramen rotundum for refractory trigeminal postherpetic neuralgia: a case report and literature review
Postherpetic neuralgia (PHN) is a debilitating complication of varicella-zoster virus infection. This case report presents a novel approach to treating refractory trigeminal maxillary postherpetic neuralgia using digital subtraction angiography (DSA)-guided peripheral nerve stimulation via the foramen rotundum. A 72-year-old female with severe, treatment-resistant pain underwent this intervention. The results demonstrated the disappearance of tactile allodynia, a significant reduction in oral analgesic requirements, and no observed complications or side effects during a 3-year follow-up period. This case highlights the potential effectiveness of DSA-guided peripheral nerve stimulation using a new dorsal root ganglion (DRG) stimulator as an alternative therapy for refractory trigeminal postherpetic neuralgia (TPHN).
- 29 February 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1353882
Open AccessDigital subtraction angiography-guided peripheral nerve stimulation via the foramen rotundum for refractory trigeminal postherpetic neuralgia: a case report and literature review
Postherpetic neuralgia (PHN) is a debilitating complication of varicella-zoster virus infection. This case report presents a novel approach to treating refractory trigeminal maxillary postherpetic neuralgia using digital subtraction angiography (DSA)-guided peripheral nerve stimulation via the foramen rotundum. A 72-year-old female with severe, treatment-resistant pain underwent this intervention. The results demonstrated the disappearance of tactile allodynia, a significant reduction in oral analgesic requirements, and no observed complications or side effects during a 3-year follow-up period. This case highlights the potential effectiveness of DSA-guided peripheral nerve stimulation using a new dorsal root ganglion (DRG) stimulator as an alternative therapy for refractory trigeminal postherpetic neuralgia (TPHN).
- Open Access
- 1 February 2024
- Published by The Korean Society of Anesthesiologists in Korean Journal of Anesthesiology
- Vol. 77 (1) , 139-155
Comparison of dexmedetomidine and opioids as local anesthetic adjuvants in patient controlled epidural analgesia: a meta-analysis
Background: Data on the efficacy and incidence of adverse effects associated with dexmedetomidine (DEX) as a local anesthetic adjuvant for patient-controlled epidural analgesia (PCEA) are inconclusive. This meta-analysis assessed the efficacy and risks of DEX for PCEA using opioids as a reference.Methods: Two researchers independently searched PubMed, Embase, Cochrane Library, and China Biology Medicine for randomized controlled trials comparing DEX and opioids as local anesthetic adjuvants in PCEA.Results: In total, 636 patients from seven studies were included in this meta-analysis. Postoperative patients who received DEX had lower visual analog scale (VAS) scores than those who received opioids at 4–8 h (mean difference [MD]: 0.61, 95% CI [0.45, 0.76], P < 0.001, I2 = 0%), 12 h (MD: 0.85, 95% CI [0.61, 1.09], P < 0.001, I2 = 0%), 24 h (MD: 0.59, 95% CI [0.06, 1.12], P = 0.030, I2 = 82%), and 48 h (MD: 0.54, 95% CI [0.05, 1.02], P = 0.030, I2 = 91%). Additionally, patients who received DEX had a lower incidence of itching (odds ratio [OR]: 2.86, 95% CI [1.18, 6.95], P = 0.020, I2 = 0%) and nausea and vomiting (OR: 6.83, 95% CI [3.63, 12.84], P < 0.001, I2 = 24%). In labor analgesia, no significant differences in neonatal (pH and PaO2 of cord blood, fetal heart rate) or maternal outcomes (duration of labor stage, mode of delivery) were found between the DEX and opioid groups.Conclusions: Compared with opioids, using DEX as a local anesthetic adjuvant in PCEA improved postoperative analgesia and reduced the incidence of itching and nausea and vomiting without increasing the incidence of adverse events.
- 1 February 2024
- Published by The Korean Society of Anesthesiologists in Korean Journal of Anesthesiology
- Vol. 77 (1) , 139-155
Open AccessComparison of dexmedetomidine and opioids as local anesthetic adjuvants in patient controlled epidural analgesia: a meta-analysis
Background: Data on the efficacy and incidence of adverse effects associated with dexmedetomidine (DEX) as a local anesthetic adjuvant for patient-controlled epidural analgesia (PCEA) are inconclusive. This meta-analysis assessed the efficacy and risks of DEX for PCEA using opioids as a reference.Methods: Two researchers independently searched PubMed, Embase, Cochrane Library, and China Biology Medicine for randomized controlled trials comparing DEX and opioids as local anesthetic adjuvants in PCEA.Results: In total, 636 patients from seven studies were included in this meta-analysis. Postoperative patients who received DEX had lower visual analog scale (VAS) scores than those who received opioids at 4–8 h (mean difference [MD]: 0.61, 95% CI [0.45, 0.76], P < 0.001, I2 = 0%), 12 h (MD: 0.85, 95% CI [0.61, 1.09], P < 0.001, I2 = 0%), 24 h (MD: 0.59, 95% CI [0.06, 1.12], P = 0.030, I2 = 82%), and 48 h (MD: 0.54, 95% CI [0.05, 1.02], P = 0.030, I2 = 91%). Additionally, patients who received DEX had a lower incidence of itching (odds ratio [OR]: 2.86, 95% CI [1.18, 6.95], P = 0.020, I2 = 0%) and nausea and vomiting (OR: 6.83, 95% CI [3.63, 12.84], P < 0.001, I2 = 24%). In labor analgesia, no significant differences in neonatal (pH and PaO2 of cord blood, fetal heart rate) or maternal outcomes (duration of labor stage, mode of delivery) were found between the DEX and opioid groups.Conclusions: Compared with opioids, using DEX as a local anesthetic adjuvant in PCEA improved postoperative analgesia and reduced the incidence of itching and nausea and vomiting without increasing the incidence of adverse events.
- Open Access
- 27 February 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 16, 1119223
Cell therapy for neuropathic pain
Neuropathic pain (NP) is caused by a lesion or a condition that affects the somatosensory system. Pathophysiologically, NP can be ascribed to peripheral and central sensitization, implicating a wide range of molecular pathways. Current pharmacological and non-pharmacological approaches are not very efficacious, with over half of NP patients failing to attain adequate pain relief. So far, pharmacological and surgical treatments have focused primarily on symptomatic relief by modulating pain transduction and transmission, without treating the underlying pathophysiology. Currently, researchers are trying to use cell therapy as a therapeutic alternative for the treatment of NP. In fact, mounting pre-clinical and clinical studies showed that the cell transplantation-based therapy for NP yielded some encouraging results. In this review, we summarized the use of cell grafts for the treatment of NP caused by nerve injury, synthesized the latest advances and adverse effects, discussed the possible mechanisms to inform pain physicians and neurologists who are endeavoring to develop cell transplant-based therapies for NP and put them into clinical practice.
- 27 February 2023
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 16, 1119223
Open AccessCell therapy for neuropathic pain
Neuropathic pain (NP) is caused by a lesion or a condition that affects the somatosensory system. Pathophysiologically, NP can be ascribed to peripheral and central sensitization, implicating a wide range of molecular pathways. Current pharmacological and non-pharmacological approaches are not very efficacious, with over half of NP patients failing to attain adequate pain relief. So far, pharmacological and surgical treatments have focused primarily on symptomatic relief by modulating pain transduction and transmission, without treating the underlying pathophysiology. Currently, researchers are trying to use cell therapy as a therapeutic alternative for the treatment of NP. In fact, mounting pre-clinical and clinical studies showed that the cell transplantation-based therapy for NP yielded some encouraging results. In this review, we summarized the use of cell grafts for the treatment of NP caused by nerve injury, synthesized the latest advances and adverse effects, discussed the possible mechanisms to inform pain physicians and neurologists who are endeavoring to develop cell transplant-based therapies for NP and put them into clinical practice.
- Open Access
- 31 January 2023
- Published by Springer Nature in Research Square
Evaluation of the clinical efficacy of oxycodone PCIA in patients with postherpetic neuralgia complicated with breakthrough pain: protocol for a prospective, double-blind, randomized controlled trial
Background: Postherpetic neuralgia (PHN) is pain that persists for 1 month or more after the shingles rash has healed, the incidence of which increases with age. Some patients with PHN will experience breakthrough pain (BTP), which is unpredictable and severe in intensity, and seriously affects patients' life quality and treatment compliance. The current clinical rescue programs are lagging behind and the effect is poor. Therefore, it has become an urgent clinical problem and research hotspot to explore timely and efficient treatment options for PHN patients with breakthrough pain. Oxycodone is widely used in the treatment of moderate to severe acute and chronic pain and cancer pain. In previous studies of cancer pain, oxycodone was found to have similar efficacy as morphine, with fewer adverse effects than morphine. The efficacy and adverse reactions of oxycodone in PHN with breakthrough pain have not been reported before. This trial intends to set up a study, using morphine as a reference, to explore the efficacy and safety of oxycodone in PHN patients with breakthrough pain, with the aim of exploring the best treatment option for patients with refractory PHN episodic pain. Methods: This study is a prospective, double-blind, randomized controlled clinical trial involving 84 PHN patients with breakthrough pain (number of outbreaks ≥ 3 times/day, NRS score ≥ 7) hospitalized in the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. At the onset of painful outbreaks, rescue medication such as morphine patient controlled intravenous analgesia (PCIA) and equal amount of oxycodone PCIA will be given. The change in NRS score before and after the administration of the drugs and the effective rate of pain control will be evaluated to assess the efficacy and safety of the different regimens. Discussion: We innovatively use oxycodone PCIA for the control of PHN episode pain, in order to shorten the duration of hospitalization and accelerate the recovery of patients. We hope to contribute our wisdom to the clinical problems that the current recue treatment of PHN breakthrough pain has significant lag and poor effect. Trial registration number ChiCTR2200065358
- 31 January 2023
- Published by Springer Nature in Research Square
Open AccessEvaluation of the clinical efficacy of oxycodone PCIA in patients with postherpetic neuralgia complicated with breakthrough pain: protocol for a prospective, double-blind, randomized controlled trial
Background: Postherpetic neuralgia (PHN) is pain that persists for 1 month or more after the shingles rash has healed, the incidence of which increases with age. Some patients with PHN will experience breakthrough pain (BTP), which is unpredictable and severe in intensity, and seriously affects patients' life quality and treatment compliance. The current clinical rescue programs are lagging behind and the effect is poor. Therefore, it has become an urgent clinical problem and research hotspot to explore timely and efficient treatment options for PHN patients with breakthrough pain. Oxycodone is widely used in the treatment of moderate to severe acute and chronic pain and cancer pain. In previous studies of cancer pain, oxycodone was found to have similar efficacy as morphine, with fewer adverse effects than morphine. The efficacy and adverse reactions of oxycodone in PHN with breakthrough pain have not been reported before. This trial intends to set up a study, using morphine as a reference, to explore the efficacy and safety of oxycodone in PHN patients with breakthrough pain, with the aim of exploring the best treatment option for patients with refractory PHN episodic pain. Methods: This study is a prospective, double-blind, randomized controlled clinical trial involving 84 PHN patients with breakthrough pain (number of outbreaks ≥ 3 times/day, NRS score ≥ 7) hospitalized in the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. At the onset of painful outbreaks, rescue medication such as morphine patient controlled intravenous analgesia (PCIA) and equal amount of oxycodone PCIA will be given. The change in NRS score before and after the administration of the drugs and the effective rate of pain control will be evaluated to assess the efficacy and safety of the different regimens. Discussion: We innovatively use oxycodone PCIA for the control of PHN episode pain, in order to shorten the duration of hospitalization and accelerate the recovery of patients. We hope to contribute our wisdom to the clinical problems that the current recue treatment of PHN breakthrough pain has significant lag and poor effect. Trial registration number ChiCTR2200065358